BSPM [Biostar Pharmaceuticals,] 8-K: Biostar Pharmaceuticals, Reports First Quarter 2011 Results; Revenuesrease

[Biostar Pharmaceuticals, Reports First Quarter 2011 Results; Revenuesrease 24% to $15.3 Million withjusted EPS of $0.11 XIANYANG, China, May 16, 2011 -- Biostar Pharmaceuticals, (Nasdaq: BSPM) ("Biostar" or "thempany"), Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acidpsules ("Xin Aoxingpsules"), and a variety of pharmaceutical products, today announced financial results for]

By | 2016-02-07T16:16:39+00:00 May 16th, 2011|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 10-Q: (Original Filing)

[FORM 10-Q (Mark One) x March 31, 2011 For the quarterly period ended: Or For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, Maryland 20-8747899 (State or other jurisdiction oforporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province Peoples Republic of China] [EMPLOYMENTREEMENT THIS EMPLOYMENTREEMENT W I T N E S S E T H: WHEREAS WHEREAS NOW, THEREFORE 1. Employment of Chief Financial Officer of thempany . 2. Term 1 4.mpensation . a. (i)Executive shall be paid a base pay of USD 10,000 per month during the term, payable on the lasty of each month.] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with] [CERTIFICATION I, Zack Pan, certify that: 1. I have reviewed this quarterly 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. ex32-1.htm 5 EX-32.1] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. ex32-2.htm 6 EX-32.2]

By | 2016-02-07T16:17:40+00:00 May 16th, 2011|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 10-Q: FORM 10-Q (Mark One) x March 31, 2011

[FORM 10-Q (Mark One) x March 31, 2011 For the quarterly period ended: Or For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, Maryland 20-8747899 (State or other jurisdiction oforporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province Peoples Republic of China] [EMPLOYMENTREEMENT THIS EMPLOYMENTREEMENT W I T N E S S E T H: WHEREAS WHEREAS NOW, THEREFORE 1. Employment of Chief Financial Officer of thempany . 2. Term 1 4.mpensation . a. (i)Executive shall be paid a base pay of USD 10,000 per month during the term, payable on the lasty of each month.] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with] [CERTIFICATION I, Zack Pan, certify that: 1. I have reviewed this quarterly 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. ex32-1.htm 5 EX-32.1] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. ex32-2.htm 6 EX-32.2]

By | 2016-02-07T16:18:33+00:00 May 16th, 2011|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)

[BioStar Pharmaceuticals Inc. Announces Appointment of New Chief Financial Officer; Appoints Audit Committee Chairman and Independent Director to the Board of Directors XIANYANG, China, April 12, 2011 – Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) (“Biostar” or “the Company”), Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsules (“Xin Aoxing Capsules”), in addition to a portfolio]

By | 2016-03-03T13:01:31+00:00 April 12th, 2011|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: BioStar Pharmaceuticals Inc. Announces Appointment of New Chief

[BioStar Pharmaceuticals Inc. Announces Appointment of New Chief Financial Officer; Appoints Audit Committee Chairman and Independent Director to the Board of Directors XIANYANG, China, April 12, 2011 – Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) (“Biostar” or “the Company”), Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsules (“Xin Aoxing Capsules”), in addition to a portfolio]

By | 2016-03-03T13:02:45+00:00 April 12th, 2011|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)

[BioStar Pharmaceuticals Announces Appointment of New Chief Financial Officer; Appoints Auditmmittee Chairman and Independent Director to the Board of Directors Finally, thempanyso announced that the Board has appointed Mr. King-fai (Patrick) Leung an independent director to the Board and Chairman of theAuditmmittee to fill vacancies resulting from Mr. Pans departures, discussedove.]

By | 2016-02-07T16:19:12+00:00 April 12th, 2011|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: BioStar Pharmaceuticals Announces Appointment of New Chief Financial

[BioStar Pharmaceuticals Announces Appointment of New Chief Financial Officer; Appoints Auditmmittee Chairman and Independent Director to the Board of Directors Finally, thempanyso announced that the Board has appointed Mr. King-fai (Patrick) Leung an independent director to the Board and Chairman of theAuditmmittee to fill vacancies resulting from Mr. Pans departures, discussedove.]

By | 2016-02-07T16:20:03+00:00 April 12th, 2011|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] SC 13G/A: (Original Filing)

[reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the liabilities of]

By | 2016-03-03T13:04:05+00:00 April 4th, 2011|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] SC 13G/A: reporting person’s initial filing on this form with

[reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the liabilities of]

By | 2016-03-03T13:05:11+00:00 April 4th, 2011|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments
Skip to toolbar